Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA application THE WOODLANDS, TX, Sept. 29, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback